Gabapentin Capsule
Product Images NDC 70518-4482

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Capsule 400 mg, oral dosage form, packaged in a quantity of 90 capsules. The label indicates repackaging by RemedyRepack Inc., Indiana, PA. It includes storage instructions and manufacturer information for Rising Pharma, Inc., Allendale, NJ. The label also provides the product NDC 70518-4482-00 and warnings to keep out of reach of children.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure of gabapentin, depicting the molecular arrangement with a cyclohexane ring, an amino group, and a carboxylic acid group connected to the central carbon atom.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

Line graph showing mean pain scores over an 8-week period comparing placebo to gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin scores decrease steadily over time, while placebo scores remain relatively constant.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

A line graph showing mean pain scores over a 7-week period for three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks, starting from baseline to week 7. The y-axis represents the mean pain score, ranging from 0 to 10. The graph illustrates a general reduction in pain scores over time for gabapentin groups compared to placebo.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates between placebo (PBO) and gabapentin (GBP) at different dosages across two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo and 32% for GBP 1800 mg and 34% for GBP 2400 mg. Statistical significance markers are noted.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot chart showing difference (%) on the vertical axis and daily dose (mg) on the horizontal axis. It compares results from three studies labeled as Study a, Study b, and Study c, each represented by different colored square markers. The chart plots data points at daily doses of 600, 900, 1200, and 1800 mg with varying percentage differences.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.